The FDA issued new warnings about antihypertensive medications which contain aliskiren (Tekturna, Amturnide,
Takamio, and Valturna) when used in combination with ACE inhibitors or
angiotensin receptor blockers (ARBs). The FDA indicates that the drug
combinations are contraindicated in patients with diabetes, and it is
adding a new warning to avoid the use of this combination in patients
with moderate to severe renal impairment (GFR <60 mL/min).
Novartis has announced it will pull Valturna from the U.S. market. Valturna contains aliskiren (Tekturna®) as
one of its ingredients.
No comments:
Post a Comment